Complications accompanying the intravesical instillation of Adriblastyne in the treatment of the superficial bladder cancer
Article published in Urologia Polska 2001/54/3.

authors

Krzysztof Bar, Robert Klijer, Waldemar Lasota, Adam Szkodny: Katedra i Klinika Urologii AM w Lublinie Kierownik kliniki: dr hab. n. med. Krzysztof Bar

keywords

urinary bladder-superficial, bladder cancer, adjuvant intravesical chemotherapy

summary

Objective. The aim of the study was the analysis of frequency and kinds of complications which occur after adjuvant intravesical chemotherapy.

Material and methods. In 1989-1994 the complications occurring in 90 cases of patients (24 women and 66 men) of the age of 24 to 75 treated to the adjuvant intravesical chemotherapy of adriblastyne were analysed prospectively.

Results. The complications occurred in 43 cases, which was 47,8 per cent. The main complications observed were: the throbocytope-nia in 18 cases (20%) and irritative symptoms in 17 cases (18,9%).

Conclusions. The adjuvant chemotherapy using adriblastyne caused the thrombocytopenia in quite many cases. This complication was observed especially between the fourth and fifth instillation.

references

1. Zincke H, Utz DC, Taylor WF et al: Influence ofthiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A pros/)ective, randomized, double-blind, controlled trial. J Urol 1983; 129; 505-509.
2. Kondas J, Szentgyorgyi E, Szokę D: Local adriamycin treatment for prevention ofrecwrence of superficial bladder tumors. Int Urol Nephrol 1988; 20; 611.
3. Newling D: Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: Experience of the EORTC group. Br J Cancer 1990; 61; 497-498.
4. Catalona WJ: Urothelial tumors of the urinaiy tract, (w) Campbell\'s Urology, 6>h ed. WB Saunders Company 1982; 1094-1158.
5. Gamick MB, Schade D, Israel M ct al: Intravesical doxorubicin for prophylaxis in the management ofrecuurrent superficial bladder carcinoma. J Urol 1984; 131; 43-46.
6. Rubbcn Laramore GE, Griffin TW et al: Natural history and treatment of low andhigh risk superficialbladdertumors. J Urol 1988; 139; 283-285.
7. Smith P: Is intravesical chemotherapy desirable in patients with superficial bladder cancer. Urol Pol 1994; 47; 8-11.
8. Kaczmarek P Miekoś E: Ocena porównawcza skuteczności leczenia preparatami BCG i Adriblastyną w grupie chorych z powierzchownymi guzami pęcherza moczowego. Uroi Pol 1997; 50 (2); 194-198.
9. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP M, Oesterlinck W, Brausi M and members of the EORTC Genitourinary Group: Treatment of superficial bladder tumors: Achievements and needs. Eur Urol 2(XK); 37 (suppl 3); 1-9.
10. Lundbeck R, Bmun E, Finerup B ct al: Intravesical therapy of noninvasive bladder tumors (stage \'lit) with doxorubicin: Initial treatment results and the long-term cowse. J Urol 1988; 139; 1212-1213.
11. Lundbeck F, Mogenscn P, Jeppersen N: Intravesical therapy of noninvasive bladder tumors with doxorubicin and urokinase. J Urol 1983; 130; 1087-1089.
12. Bar K: Ocena wyników leczenia nowotworów pęcherza moczowego za pomocą ekktroresekcji pizezcewkowej i lasera neodymowego Nd: YAGz uwzględnieniem znaczenia badania histopatologicznego w diagnostyce tego schorzenia. Rozprawa habilitacyjna. Śląska Akademia Medyczna w Katowicach 1994; 41-42.
13. Webb JN: The histopathology of bladder cancer: Bladder cancer. Ed Zingg EJ and Wallace DM A Springer Vcrlag, Berlin, Heidelberg. 1985; 23-24.

correspondence